Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 2,086 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Open Label Extension Study Clear all

Conditions: Adult Growth Hormone Deficiency
Interventions: ALTU-238; Drug
Lead sponsor: Altus Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Louisville, Kentucky • Galveston, Texas • San Antonio, Texas

Conditions: CKD, ESRD
Interventions: Long term hemodialysis catheter; Device
Lead sponsor: Medical Components, Inc dba MedComp; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Rheumatoid Arthritis
Interventions: Filgotinib, Placebo to match filgotinib; Drug
Lead sponsor: Alfasigma S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 2,731 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 72
States / cities: Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more

Conditions: Neoplasms
Interventions: RO6874813; Biological
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Metastatic Castration-Resistant Prostate Cancer
Interventions: [Lu-177]-PNT2002, Abiraterone, Enzalutamide; Drug
Lead sponsor: POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 33
States / cities: Tucson, Arizona • Los Angeles, California • Newport Beach, California + 24 more

Conditions: Healthy
Interventions: Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Attention-Deficit/Hyperactivity Disorder
Interventions: SPN-812; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 4 Years to 18 Years
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 16
States / cities: Little Rock, Arkansas • Long Beach, California • Colorado Springs, Colorado + 10 more

Conditions: Bullous Pemphigoid
Interventions: efgartigimod PH20 SC, Prednisone; Biological · Drug
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Phoenix, Arizona • Fountain Valley, California • Miami, Florida + 3 more

Conditions: Atherosclerosis
Interventions: Darapladib, Diltiazem; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: SPD503, VYVANSE, SPD503 and VYVANSE; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Food Allergy
Interventions: ADP101; Biological
Lead sponsor: Alladapt Immunotherapeutics, Inc.; Industry
Eligibility: 4 Years to 57 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 14
States / cities: Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 11 more

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Aptensio XR; Drug
Lead sponsor: Rhodes Pharmaceuticals, L.P.; Industry
Eligibility: 4 Years to 6 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Las Vegas, Nevada • Durham, North Carolina

Conditions: Cognition Disorders
Interventions: Placebo, Solanezumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 1,169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 62
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 47 more

Conditions: Primary Biliary Cirrhosis
Interventions: Obeticholic Acid; Drug
Lead sponsor: Intercept Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 7
States / cities: La Jolla, California • Sacramento, California • Miami, Florida + 4 more

Conditions: Pre-Exposure Prophylaxis of HIV Infection
Interventions: Lenacapavir Injection, Lenacapavir Tablet, Emtricitabine/tenofovir disoproxil fumarate (F/TDF); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: Los Angeles, California • San Diego, California • Miami, Florida + 6 more

Conditions: Autism, Pediatric Autism
Interventions: Memantine HCl; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 19
States / cities: Phoenix, Arizona • Sacramento, California • San Francisco, California + 14 more

Conditions: Kidney Transplantation
Interventions: Tacrolimus Modified Release (MR), tacrolimus; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 7
States / cities: San Diego, California • Miami, Florida • Minneapolis, Minnesota + 4 more

Conditions: Becker Muscular Dystrophy
Interventions: Sevasemten; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: Male only
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 24
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 21 more

Conditions: Chronic Graft Versus Host Disease cGVHD
Interventions: Efavaleukin Alfa; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 8
States / cities: Duarte, California • Tampa, Florida • Atlanta, Georgia + 5 more

Conditions: Congenital Adrenal Hyperplasia
Interventions: Chronocort; Drug
Lead sponsor: Immedica Pharma AB; Industry
Eligibility: 16 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 11
States / cities: Los Angeles, California • Orange, California • Jacksonville, Florida + 8 more

Conditions: Rheumatoid Arthritis
Interventions: ATN-103; Drug
Lead sponsor: Ablynx, a Sanofi company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 25
States / cities: Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 22 more

Conditions: Pain, Advanced Cancer
Interventions: Nabiximols; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 37
States / cities: Phoenix, Arizona • El Cajon, California • Gilroy, California + 31 more

Conditions: Thrombocytopenia
Interventions: Avatrombopag, Placebo, Pegylated interferon (PEG-IFN), Telaprevir, Ribavirin; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Los Angeles, California • Fairfax, Virginia

Conditions: Psoriasis
Interventions: Rimegepant, Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: New York, New York

Search by objective public record fields.

Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety

Long Term Hemodialysis Catheters (LTHD) Post Market Clinical Follow up (PMCF)

Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule)

A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).

A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers

Open-label Extension Study of ADP101

A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD

Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103)

Open-label Study of Safety and Tolerability of Memantine in Children With Autism

A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients

Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy

Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease

Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia

Study Evaluating Long-Term Safety Of ATN-103 In Subjects With Rheumatoid Arthritis

Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

Rimegepant in Moderate Plaque-type Psoriasis